Molecular markers in Paget disease of the breast

Fu, Wei; Lobocki, Catherine; Silberberg, Boris; Chelladurai, Mohanathasan; Young, Shun C.

doi:10.1002/jso.1090

Cited by 82 publications

(52 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognosis of these patients depends on the presence of lump and associated lymph node metastases. They have found that overall survival correlates with lymph node status, with node-negative patients having a survival of 75-95 % whereas in node-positive patients, it was 20-25 % [6,23].…”

Section: Discussionmentioning

confidence: 99%

Challenges in Diagnosis and Management of Paget’s Disease of the Breast—a Retrospective Study

Challa

Deshmane

2014

Indian J Surg

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Challenges in Diagnosis and Management of Paget’s Disease of the Breast—a Retrospective Study

Challa

Deshmane

2014

Indian J Surg

View full text Add to dashboard Cite

“…For example, in one study, only one of 73 grade I IDC cases and one of 67 low-grade classic ILC cases showed HER-2 amplification detected by FISH [86]. HER-2 overexpression and HER-2 amplification have been a consistent feature of both mammary and extramammary Paget's disease [124,125] (Fig. 2).…”

Section: Her-2 Expression and Breast Pathologymentioning

confidence: 99%

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

et al. 2009

View full text Add to dashboard Cite

1. Contrast the current strengths and limitations of the three main slide-based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer tissues for HER-2 status.2. Compare the efficacy of trastuzumab-and lapatinib-based regimens in the adjuvant and metastatic settings as reported in published clinical trials and regulatory approval databases.3. Contrast the list of biomarkers that have been associated with clinical resistance to trastuzumab and lapatinib and describe their current level of validation.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACTThe human epidermal growth factor receptor (HER-2) oncogene encodes a transmembrane tyrosine kinase receptor that has evolved as a major classifier of invasive breast cancer and target of therapy for the disease. The validation of the general prognostic significance of HER-2 gene amplification and protein overexpression in the absence of anti-HER-2 targeted therapy is discussed in a study of 107 published studies involving 39,730 patients, which produced an overall HER-2-positive rate of 22.2% and a mean relative risk for overall survival (OS) of 2.74. The issue of HER-2 status in primary versus metastatic breast cancer is considered along with a section on the features of metastatic HER-2-positive disease. The major marketed slide-based HER-2 testing approaches, immunohistochemistry, fluorescence in situ hybridization, and chromogenic in situ

show abstract

“…Only 1 of 73 grade I invasive ductal carcinomas and 1 of 67 classic lobular carcinomas showed amplification of the HER-2/neu gene. HER-2/neu overexpression has been a consistent feature of both mammary and extramammary Paget's disease [173,174]. The majority of studies that have compared HER-2/neu status in paired primary and metastatic tumor tissues have found an overwhelming consistency of the patient's status regardless of the method of testing (IHC versus FISH) [175][176][177][178][179][180].…”

Section: Her-2/neu Expression and Breast Pathologymentioning

confidence: 99%

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

et al. 2003

View full text Add to dashboard Cite

The HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor with extensive homology to the epidermal growth factor receptor. In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages and disadvantages of Southern blotting, polymerase chain reaction amplification, andThe Oncologist 2003;8:307-325 www.TheOncologist.comCorrespondence: Jeffrey S. Ross, M.D., Albany Medical College, Department of Pathology, Mail Code 81, 47 New Scotland Avenue, Albany, New York 12208, USA. Telephone: 518-262-5461; Fax: 518-262-8092; e-mail: rossj@mail.amc.edu Received February 5, 2003; accepted for publication April 28, 2003. ©AlphaMed Press 1083-7159/2003 The Oncologist ® LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Define the historical background and biological basis of the discovery of the HER-2/neu gene and its first use as a prognostic factor in breast cancer.2. Recall the uses of HER-2/neu testing prior to the approval of trastuzumab including the impact on anthracycline adjuvant and first-line chemotherapy responses.3. Explain the basic principles of all the HER-2/neu tests in clinical practice: IHC, FISH, Southern blot, PCR, tissue ELISA, and serum ELISA.4. Contrast the pros and cons and uses and limitations of the IHC versus the FISH approach to HER-2/neu testing.5. Critique the most recent data comparing IHC with FISH for the prediction of response to single-agent trastuzumab and trastuzumab in combination with standard chemotherapy for advanced metastatic breast cancer.6. Describe the HER-2/neu expression patterns in all types of breast conditions, including in situ carcinoma, lobular versus ductal carcinoma, Paget's disease, male breast cancer, breast sarcomas, and benign breast disorders.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Ross, Fletcher, Linette et al. 308 HER-2/NEU GENE (C-ERBB-2)The human epidermal growth factor receptor 2 (HER-2)/neu (c-erbB-2) gene is localized to chromosome 17q and encodes a transmembrane tyrosine kinase receptor protein that is a member of the epidermal growth factor receptor (EGFR) or HER family ( Fig. 1) [1]. This family of receptors is involved in cell-to-cell and cell-to-stroma communication primarily through a process known as signal transduction, in which external growth factors, or ligands, affect the transcription of various genes by phosphorylating or dephosphorylating a series of transmembrane proteins and intracellular signaling intermediates, many of which possess enzymatic activity. Signal propagation occurs as the enzymatic activity of one protein turns on the enzymat...

show abstract

Molecular markers in Paget disease of the breast

Cited by 82 publications

References 38 publications

Challenges in Diagnosis and Management of Paget’s Disease of the Breast—a Retrospective Study

Challenges in Diagnosis and Management of Paget’s Disease of the Breast—a Retrospective Study

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

Contact Info

Product

Resources

About